[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA Cancer J Clin, vol. 68, no. 6, pp. 394-424, 2018.
[2] W. Chen, R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X. Q. Yu and J. He, "Cancer statistics in China, 2015," CA Cancer J Clin, vol. 66, no. 2, pp. 115-132, 2016.
[3] K. A. Cronin, A. J. Lake, S. Scott, R. L. Sherman, A. M. Noone, N. Howlader, S. J. Henley, R. N. Anderson, A. U. Firth, J. Ma, B. A. Kohler and A. Jemal, "Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics," Cancer, vol. 124, no. 13, pp. 2785-2800, 2018.
[4] C. Ma, M. Han, B. Heinrich, Q. Fu, Q. Zhang, M. Sandhu, D. Agdashian, M. Terabe, J. A. Berzofsky, V. Fako, T. Ritz, T. Longerich, C. M. Theriot, J. A. McCulloch, S. Roy, W. Yuan, V. Thovarai, S. K. Sen, M. Ruchirawat, F. Korangy, X. W. Wang, G. Trinchieri and T. F. Greten, "Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells," Science, vol. 360, no. 6391, 2018.
[5] M. Effenberger and H. Tilg, "The intestinal microbiota and hepatocellular carcinoma," memo-Magazine of European Medical Oncology, vol. 13, no. 2, pp. 223-226, 2020.
[6] A. F. Hofmann, "The continuing importance of bile acids in liver and intestinal disease," Arch Intern Med, vol. 159, no. 22, pp. 2647-2658, 1999.
[7] E. Martinot, L. Sedes, M. Baptissart, J. M. Lobaccaro, F. Caira, C. Beaudoin and D. H. Volle, "Bile acids and their receptors," Mol Aspects Med, vol. 56, pp. 2-9, 2017.
[8] D. W. Russell, "Fifty years of advances in bile acid synthesis and metabolism," J Lipid Res, vol. 50 Suppl, pp. S120-125, 2009.
[9] F. M. Vaz and S. Ferdinandusse, "Bile acid analysis in human disorders of bile acid biosynthesis," Mol Aspects Med, vol. 56, pp. 10-24, 2017.
[10] T. M. Sarenac and M. Mikov, "Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients," Front Pharmacol, vol. 9, pp. 939, 2018.
[11] B. Staels and V. A. Fonseca, "Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration," Diabetes Care, vol. 32 Suppl 2, pp. S237-245, 2009.
[12] M. Begley, C. G. Gahan and C. Hill, "The interaction between bacteria and bile," FEMS Microbiol Rev, vol. 29, no. 4, pp. 625-651, 2005.
[13] P. A. Dawson and S. J. Karpen, "Intestinal transport and metabolism of bile acids," J Lipid Res, vol. 56, no. 6, pp. 1085-1099, 2015.
[14] M. Trauner and J. L. Boyer, "Bile salt transporters: molecular characterization, function, and regulation," Physiol Rev, vol. 83, no. 2, pp. 633-671, 2003.
[15] V. Cruz-Ramon, P. Chinchilla-Lopez, O. Ramirez-Perez and N. Mendez-Sanchez, "Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances," Ann Hepatol, vol. 16 Suppl 1, pp. S58-S67, 2017.
[16] L. Vitek, "Bile Acids in the Treatment of Cardiometabolic Diseases," Ann Hepatol, vol. 16 Suppl 1, pp. S43-S52, 2017.
[17] C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx and K. Schoonjans, "Targeting bile-acid signalling for metabolic diseases," Nat Rev Drug Discov, vol. 7, no. 8, pp. 678-693, 2008.
[18] B. Jia and C. O. Jeon, "Promotion and induction of liver cancer by gut microbiome-mediated modulation of bile acids," PLoS Pathog, vol. 15, no. 9, pp. e1007954, 2019.
[19] T. Sarenac and M. Mikov, "Cervical Cancer, Different Treatments and Importance of Bile Acids as Therapeutic Agents in This Disease," Front Pharmacol, vol. 10, pp. 484, 2019.
[20] Y. C. Wu, C. F. Chiu, C. T. Hsueh and C. T. Hsueh, "The role of bile acids in cellular invasiveness of gastric cancer," Cancer Cell Int, vol. 18, pp. 75, 2018.
[21] S. Ocvirk and S. J. O'Keefe, "Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions," Curr Nutr Rep, vol. 6, no. 4, pp. 315-322, 2017.
[22] H. Zeng, S. Umar, B. Rust, D. Lazarova and M. Bordonaro, "Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer," Int J Mol Sci, vol. 20, no. 5, 2019.
[23] W. Lee, J. Um, B. Hwang, Y. C. Lee, B. C. Chung and J. Hong, "Assessing the progression of gastric cancer via profiling of histamine, histidine, and bile acids in gastric juice using LC-MS/MS," J Steroid Biochem Mol Biol, vol. 197, pp. 105539, 2019.
[24] J. Reimand, R. Isserlin, V. Voisin, M. Kucera, C. Tannus-Lopes, A. Rostamianfar, L. Wadi, M. Meyer, J. Wong, C. Xu, D. Merico and G. D. Bader, "Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap," Nat Protoc, vol. 14, no. 2, pp. 482-517, 2019.
[25] Y. Benjamini and Y. Hochberg, "Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing," Journal of the Royal Statistical Society Series B-Statistical Methodology, vol. 57, no. 1, pp. 289-300, 1995.
[26] N. Asomaning and K. J. Archer, "High-throughput DNA methylation datasets for evaluating false discovery rate methodologies," Comput Stat Data Anal, vol. 56, no. 6, pp. 1748-1756, 2012.
[27] M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin and G. Sherlock, "Gene ontology: tool for the unification of biology. The Gene Ontology Consortium," Nat Genet, vol. 25, no. 1, pp. 25-29, 2000.
[28] M. Kanehisa, S. Goto, S. Kawashima and A. Nakaya, "The KEGG databases at GenomeNet," Nucleic Acids Res, vol. 30, no. 1, pp. 42-46, 2002.
[29] B. Chen, S. Huang, T. R. Pisanic, A. Stark, Y. Tao, B. Cheng, Y. Li, Y. Wei, W. Zhao and T.-H. Wang, "Rab8 GTPase regulates Klotho-mediated inhibition of cell growth and progression by directly modulating its surface expression in human non-small cell lung cancer," EBioMedicine, vol. 49, pp. 118-132, 2019.
[30] F. Pons, M. Varela and J. M. Llovet, "Staging systems in hepatocellular carcinoma," Hpb, vol. 7, no. 1, pp. 35-41, 2005.
[31] P. L. Jansen, "Endogenous bile acids as carcinogens," J Hepatol, vol. 47, no. 3, pp. 434-435, 2007.
[32] J. Y. L. Chiang and J. M. Ferrell, "Bile Acid Metabolism in Liver Pathobiology," Gene Expr, vol. 18, no. 2, pp. 71-87, 2018.
[33] X. Wang, X. Fu, C. Van Ness, Z. Meng, X. Ma and W. Huang, "Bile Acid Receptors and Liver Cancer," Curr Pathobiol Rep, vol. 1, no. 1, pp. 29-35, 2013.
[34] M. Chen, J. E. Drury and T. M. Penning, "Substrate specificity and inhibitor analyses of human steroid 5beta-reductase (AKR1D1)," Steroids, vol. 76, no. 5, pp. 484-490, 2011.
[35] S. J. Steinberg, S. J. Mihalik, D. G. Kim, D. A. Cuebas and P. A. Watkins, "The human liver-specific homolog of very long-chain acyl-CoA synthetase is cholate:CoA ligase," J Biol Chem, vol. 275, no. 21, pp. 15605-15608, 2000.
[36] F. Hirche, M. Fischer, J. Keller and K. Eder, "Determination of carnitine, its short chain acyl esters and metabolic precursors trimethyllysine and gamma-butyrobetaine by quasi-solid phase extraction and MS/MS detection," J Chromatogr B Analyt Technol Biomed Life Sci, vol. 877, no. 22, pp. 2158-2162, 2009.
[37] A. Ohkuni, Y. Ohno and A. Kihara, "Identification of acyl-CoA synthetases involved in the mammalian sphingosine 1-phosphate metabolic pathway," Biochem Biophys Res Commun, vol. 442, no. 3-4, pp. 195-201, 2013.
[38] S. Miyazawa, T. Sakurai, Y. Shindo, M. Imura and T. Hashimoto, "The effect of tryptophan administration on fatty acid synthesis in the livers of rats under various nutritional conditions," J Biochem, vol. 78, no. 1, pp. 139-147, 1975.
[39] T. Suzuki, A. V. Delgado-Escueta, K. Aguan, M. E. Alonso, J. Shi, Y. Hara, M. Nishida, T. Numata, M. T. Medina, T. Takeuchi, R. Morita, D. Bai, S. Ganesh, Y. Sugimoto, J. Inazawa, J. N. Bailey, A. Ochoa, A. Jara-Prado, A. Rasmussen, J. Ramos-Peek, S. Cordova, F. Rubio-Donnadieu, Y. Inoue, M. Osawa, S. Kaneko, H. Oguni, Y. Mori and K. Yamakawa, "Mutations in EFHC1 cause juvenile myoclonic epilepsy," Nat Genet, vol. 36, no. 8, pp. 842-849, 2004.
[40] J. Y. Chiang, "Bile acids: regulation of synthesis," J Lipid Res, vol. 50, no. 10, pp. 1955-1966, 2009.
[41] S. Fiorucci and E. Distrutti, "The Pharmacology of Bile Acids and Their Receptors," Handb Exp Pharmacol, vol. 256, pp. 3-18, 2019.
[42] X. Wang, B. Cai, X. Yang, O. O. Sonubi, Z. Zheng, R. Ramakrishnan, H. Shi, L. Valenti, U. B. Pajvani, J. Sandhu, R. E. Infante, A. Radhakrishnan, D. F. Covey, K. L. Guan, J. Buck, L. R. Levin, P. Tontonoz, R. F. Schwabe and I. Tabas, "Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis," Cell Metab, vol. 31, no. 5, pp. 969-986 e967, 2020.
[43] P. Rosignoli, R. Fabiani, A. De Bartolomeo, R. Fuccelli, M. A. Pelli and G. Morozzi, "Genotoxic effect of bile acids on human normal and tumour colon cells and protection by dietary antioxidants and butyrate," Eur J Nutr, vol. 47, no. 6, pp. 301-309, 2008.
[44] M. Dall'Agnol, C. Bernstein, H. Bernstein, H. Garewal and C. M. Payne, "Identification of S-nitrosylated proteins after chronic exposure of colon epithelial cells to deoxycholate," Proteomics, vol. 6, no. 5, pp. 1654-1662, 2006.
[45] S. Sydor, J. Best, I. Messerschmidt, P. Manka, R. Vilchez-Vargas, S. Brodesser, C. Lucas, A. Wegehaupt, C. Wenning, S. Assmuth, S. Hohenester, A. Link, K. N. Faber, H. Moshage, F. J. Cubero, S. L. Friedman, G. Gerken, M. Trauner, A. Canbay and L. P. Bechmann, "Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC," Clin Transl Gastroenterol, vol. 11, no. 3, pp. e00131, 2020.
[46] E. Lozano, L. Sanchez-Vicente, M. J. Monte, E. Herraez, O. Briz, J. M. Banales, J. J. Marin and R. I. Macias, "Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development," Mol Cancer Res, vol. 12, no. 1, pp. 91-100, 2014.
[47] E. Manieri, C. Folgueira, M. E. Rodriguez, L. Leiva-Vega, L. Esteban-Lafuente, C. Chen, F. J. Cubero, T. Barrett, J. Cavanagh-Kyros, D. Seruggia, A. Rosell, F. Sanchez-Cabo, M. J. Gomez, M. J. Monte, G. M. JJ, R. J. Davis, A. Mora and G. Sabio, "JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma," Proc Natl Acad Sci U S A, 2020.
[48] L. Sun, K. Beggs, P. Borude, G. Edwards, B. Bhushan, C. Walesky, N. Roy, M. W. Manley, Jr., S. Gunewardena, M. O'Neil, H. Li and U. Apte, "Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling," Am J Physiol Gastrointest Liver Physiol, vol. 311, no. 1, pp. G91-G104, 2016.
[49] W. Jia, G. Xie and W. Jia, "Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis," Nat Rev Gastroenterol Hepatol, vol. 15, no. 2, pp. 111-128, 2018.